Gastrointestinal Cancer

>

Latest News

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.
Nivolumab Combo Earns Positive CHMP Opinion in Advanced Liver Cancer

February 1st 2025

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.
Top 5 Takeaways for Gastrointestinal Cancer Management From 2025 ASCO GI

January 30th 2025

Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC
Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC

January 30th 2025

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.
Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs

January 29th 2025

T-DM1 Shows Promise in HER2+ Biliary Tract Cancer
T-DM1 Shows Promise in HER2+ Biliary Tract Cancer

January 28th 2025

Latest CME Events & Activities

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

<1
...
4950515253